Daniel G. Hackam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel G. Hackam has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Anatoly Langer
Terrence Donnelly Heart Center, Division of Cardiology, St Michael’s Hospital, University of Toronto, Toronto, Canada
1 shared publicationDeva Thiruchelvam
1 shared publicationDonald A Redelmeier
1 shared publicationEtienne A. Grima
Canadian Heart Research Center, Toronto, Canada
1 shared publication- John David Spence
Affiliation Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, Western University, London, Canada
1 shared publication - John William Eikelboom
McMaster University
1 shared publication
Latest Publications
- 1 June 2007
- Published by Wolters Kluwer Health in Stroke
- Vol. 38 (6) , 1881-1885
Combining Multiple Approaches for the Secondary Prevention of Vascular Events After Stroke
Background and Purpose— Numerous effective strategies for the secondary prevention of cardiovascular events in high-risk patients have now been established. We sought to calculate the cumulative benefit of combining multiple strategies for preventing recurrent events in patients with a history of ischemic stroke or transient ischemic attack. Methods— A comprehensive literature search was undertaken to identify meta-analyses of randomized controlled trials reporting on the efficacy of secondary prevention strategies. The baseline incidence of vascular events was modeled from the Life Long After Cerebral Ischemia study. Strategies were combined on a multiplicative scale and cumulative risk reductions were computed over a 5-year interval. Results— The combination of 5 proven strategies applied to survivors of an initial stroke or transient ischemic attack—dietary modification, exercise, aspirin, a statin, and an antihypertensive agent—could result in a cumulative relative risk reduction of 80%. Given a 5-year major cardiovascular event rate of 24%, this translates to a number needed to treat of about 5. Further gains would result from applying multimodality therapy over longer intervals and enriching the base strategy with dual antiplatelet therapy, high-dose statins, and more intensive blood pressure–lowering. Even more benefit would be present in high-risk subgroups with the addition, where appropriate, of carotid endarterectomy, moderate intensity oral anticoagulants, glycemic control, and smoking cessation. Conclusions— At least four-fifths of recurrent vascular events in patients with cerebrovascular disease might be prevented by application of a comprehensive, multifactorial approach.
- 1 June 2007
- Published by Wolters Kluwer Health in Stroke
- Vol. 38 (6) , 1881-1885
Combining Multiple Approaches for the Secondary Prevention of Vascular Events After Stroke
Background and Purpose— Numerous effective strategies for the secondary prevention of cardiovascular events in high-risk patients have now been established. We sought to calculate the cumulative benefit of combining multiple strategies for preventing recurrent events in patients with a history of ischemic stroke or transient ischemic attack. Methods— A comprehensive literature search was undertaken to identify meta-analyses of randomized controlled trials reporting on the efficacy of secondary prevention strategies. The baseline incidence of vascular events was modeled from the Life Long After Cerebral Ischemia study. Strategies were combined on a multiplicative scale and cumulative risk reductions were computed over a 5-year interval. Results— The combination of 5 proven strategies applied to survivors of an initial stroke or transient ischemic attack—dietary modification, exercise, aspirin, a statin, and an antihypertensive agent—could result in a cumulative relative risk reduction of 80%. Given a 5-year major cardiovascular event rate of 24%, this translates to a number needed to treat of about 5. Further gains would result from applying multimodality therapy over longer intervals and enriching the base strategy with dual antiplatelet therapy, high-dose statins, and more intensive blood pressure–lowering. Even more benefit would be present in high-risk subgroups with the addition, where appropriate, of carotid endarterectomy, moderate intensity oral anticoagulants, glycemic control, and smoking cessation. Conclusions— At least four-fifths of recurrent vascular events in patients with cerebrovascular disease might be prevented by application of a comprehensive, multifactorial approach.
Translating animal research into clinical benefit
Footnotes ARTICLE Competing interests: None declared.
Translating animal research into clinical benefit
Footnotes ARTICLE Competing interests: None declared.
Antithrombotic treatment for peripheral arterial disease
Context: Patients with peripheral arterial disease (PAD) bear a substantial risk for vascular events in the coronary, cerebral and peripheral circulations. In addition, this disorder is associated with a systemic milieu characterised by ongoing platelet activation and heightened thrombogenesis. Objective: To determine the optimal antithrombotic prophylaxis for patients with PAD. Data sources: Using terms related to PAD and antithrombotic agents, we searched the following databases for relevant articles: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, the National Institutes of Health Clinical Trials Database, Web of Science, and the International Pharmaceutical Abstracts Database (search dates: 1 January 1990 to 1 January 2007). Additional articles were identified from cardiovascular and vascular surgery conference proceedings, bibliographies of review articles, and personal files. Study selection: We focused on randomised trials, systematic reviews and consensus guidelines of antithrombotic therapies for PAD. Data extraction: Detailed study information was abstracted by each author working independently. Results: Multiple studies show that patients with PAD manifest platelet hyperaggregability, increased levels of soluble platelet activation markers, enhanced thrombin generation and altered fibrinolytic potential. Many of these markers predict subsequent cardiovascular events. Available randomised trials and meta-analyses show that most available antithrombotic agents prevent major cardiovascular events and death in patients with PAD, including aspirin, aspirin/dipyridamole, clopidogrel, ticlopidine, picotamide and oral anticoagulants. Conclusions: Although the most favourable risk-benefit profile, cost-effectiveness and overall evidence base supports aspirin in this setting, we provide scenarios in which alternatives to aspirin should be considered.
Antithrombotic treatment for peripheral arterial disease
Context: Patients with peripheral arterial disease (PAD) bear a substantial risk for vascular events in the coronary, cerebral and peripheral circulations. In addition, this disorder is associated with a systemic milieu characterised by ongoing platelet activation and heightened thrombogenesis. Objective: To determine the optimal antithrombotic prophylaxis for patients with PAD. Data sources: Using terms related to PAD and antithrombotic agents, we searched the following databases for relevant articles: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, the National Institutes of Health Clinical Trials Database, Web of Science, and the International Pharmaceutical Abstracts Database (search dates: 1 January 1990 to 1 January 2007). Additional articles were identified from cardiovascular and vascular surgery conference proceedings, bibliographies of review articles, and personal files. Study selection: We focused on randomised trials, systematic reviews and consensus guidelines of antithrombotic therapies for PAD. Data extraction: Detailed study information was abstracted by each author working independently. Results: Multiple studies show that patients with PAD manifest platelet hyperaggregability, increased levels of soluble platelet activation markers, enhanced thrombin generation and altered fibrinolytic potential. Many of these markers predict subsequent cardiovascular events. Available randomised trials and meta-analyses show that most available antithrombotic agents prevent major cardiovascular events and death in patients with PAD, including aspirin, aspirin/dipyridamole, clopidogrel, ticlopidine, picotamide and oral anticoagulants. Conclusions: Although the most favourable risk-benefit profile, cost-effectiveness and overall evidence base supports aspirin in this setting, we provide scenarios in which alternatives to aspirin should be considered.
- 1 October 2006
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 44 (4) , 776-781
Supporting a call to action for peripheral artery disease: Insights from two prospective clinical registries
- 1 October 2006
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 44 (4) , 776-781
Supporting a call to action for peripheral artery disease: Insights from two prospective clinical registries
- 1 August 2006
- Published by Elsevier in The Lancet
- Vol. 368 (9536) , 659-665
Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study
- 1 August 2006
- Published by Elsevier in The Lancet
- Vol. 368 (9536) , 659-665
Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study
- 31 March 2006
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 43 (3) , 632-634
Perioperative β-blocker therapy in vascular surgery: Clinical update
- 31 March 2006
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 43 (3) , 632-634
Perioperative β-blocker therapy in vascular surgery: Clinical update
- 1 January 2006
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 6 (6) , 367-371
Intensive Reduction of Low-Density Lipoprotein-Cholesterol
- 1 January 2006
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 6 (6) , 367-371
Intensive Reduction of Low-Density Lipoprotein-Cholesterol